Nanogen and Fisher Scientific Expand Molecular Diagnostics R&D Collaboration Agreement

Aug 03, 2006, 01:00 ET from Nanogen, Inc.

    SAN DIEGO and HAMPTON, N.H., Aug. 3 /PRNewswire-FirstCall/ -- Nanogen,
 Inc. (Nasdaq:   NGEN), a developer of advanced diagnostic products, and
 Fisher Scientific International Inc. (NYSE:   FSH) announced today that the
 companies have expanded their relationship to include a research and
 development collaboration in molecular diagnostics. The collaboration
 agreement complements Fisher's equity investment in Nanogen announced in
 March 2006.
     Nanogen and Fisher agreed to share technology and patent rights
 specifically for the development, manufacture and marketing of new
 molecular diagnostic products. Under the agreement, Fisher Scientific may
 provide up to $10 million in total during 2007 and 2008 for the research
 and development of infectious disease and molecular diagnostic tests that
 will be mutually agreed upon. The extensive knowledge, intellectual
 property and capabilities of both companies will enable molecular
 diagnostic products to be brought to the market more quickly.
     Additionally, Nanogen and Athena Diagnostics, a wholly owned subsidiary
 of Fisher Scientific International, have agreed to develop, manufacture and
 market products based on Athena's proprietary biomarkers for research and
 for in vitro diagnostic use. Athena has an extensive portfolio of unique
 markers in the fields of neurology and endocrinology that it has
 successfully incorporated into its testing service, several of which could
 be incorporated into assays for use on Nanogen's microarray platform, the
 NanoChip(R)400. Nanogen likewise has access to a wide range of markers that
 could be used to create unique tests for the Athena Diagnostics testing
     "We see tremendous opportunities in molecular diagnostics and are
 pleased to be expanding our presence in this rapidly growing market," said
 Leland Foster, chief science officer for Fisher Scientific International.
 "By fostering a collaboration between Nanogen and Athena and furthering
 Nanogen's R&D efforts, we are advancing the abilities of both companies to
 bring diagnostic products to the marketplace."
     Howard C. Birndorf, chairman and CEO of Nanogen, added, "We are very
 pleased to further develop our relationship with Fisher. Both companies
 share the belief that molecular diagnostics will play a fundamental role in
 the drive toward personalized healthcare, and we are excited to work
 together in this endeavor."
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose,
 and ultimately help treat disease. The company's products include real-time
 PCR reagents, the NanoChip(R) electronic microarray platform and a line of
 rapid diagnostic tests. Nanogen's ten years of pioneering research
 involving nanotechnology holds the promise of miniaturization and continues
 to be supported for its potential for diagnostic and biodefense
 applications. For additional information please visit Nanogen's website at
     About Fisher Scientific International Inc.
     Fisher Scientific International Inc. (NYSE:   FSH) is a leading provider
 of products and services to the scientific community. Fisher facilitates
 discovery by supplying researchers and clinicians in labs around the world
 with the tools they need. We serve pharmaceutical and biotech companies;
 colleges and universities; medical-research institutions; hospitals;
 reference, quality-control, process-control and R&D labs in various
 industries; as well as government agencies. From biochemicals, cell-culture
 media and proprietary RNAi technology to rapid-diagnostic tests, safety
 products and other consumable supplies, Fisher provides more than 600,000
 products and services. This broad offering, combined with Fisher's globally
 integrated supply chain and unmatched sales and marketing capabilities,
 helps make our 350,000 customers more efficient and effective at what they
     Founded in 1902, Fisher Scientific is a FORTUNE 500 company and is a
 component of the S&P 500 Index. With approximately 19,500 employees
 worldwide, the company had revenues of $5.6 billion in 2005. Fisher
 Scientific is a company committed to delivering on our promises -- to
 customers, shareholders and employees alike. Additional information about
 Fisher is available on the company's Web site at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements,
 including whether the relationship between Nanogen, Fisher and Athena will
 become a material collaboration, whether patents owned or licensed will be
 developed into products, whether the patents offer any protection against
 competitors with competing technologies, whether products under development
 can be successfully developed and commercialized, whether results reported
 by customers or partners can be identically replicated, whether the market
 for molecular diagnostics technologies and products will further develop,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in Nanogen's and Fisher Scientific
 International's Form 10-K or Form 10-Q most recently filed with the
 Securities and Exchange Commission. These forward-looking statements speak
 only as of the date hereof. Nanogen and Fisher Scientific International
 disclaim any intent or obligation to update these forward-looking

SOURCE Nanogen, Inc.